宫颈癌血清精子相关抗原9的表达水平及临床意义

摘要

Objective The detection of serum sperm related antigen expression level 9(SPAG9)in patients with cervical cancer,and analyze its role in occurrence and development of cervical cancer and its clinical significance.Methods 96 patients with cervical cancer(the observation group)were selected in our hospital from January in 2012 to August in 2015.The clinical stages:I~stage Ⅱ 45 cases,Ⅲ~Ⅳ 51 cases. Pathology classification:high differentiation 40 cases,56 cases of low differentiation.Squamous carcinoma 44 cases and adenocarcinoma 52 cases respectively.54 patients withoutt lymph node metastasis,42 cases with lymph node metastasis. 84 women(the control group)with normal cervix cases were selected. the main object of observation group study,serum levels of SPAG9 and testing different clinical stage,differentiation,tumor type, lymph node metastasis and SPAG9 level before and after treatment.Results The serum SPAG9 OD value of the observation group 193.80±13.61, higher than the control group 65.73 ±11.85,there were statistically significant difference(P<0.05).The SPAG9 OD value of the observation group after treatment was 117.69±12.30,lower than before treatment,the difference was statistically significant(P<0.05). The serum SPAG9 OD values of the patients with cervical cancer Ⅲ~Ⅳ period,low differentiation and lymph node metastasis were 227.61±13.21,213.19±12.86 and 12.86±12.93, higher than the patients withⅠ~Ⅱ level,high differentiation and the patients without lymphatic metastasis,there was statistically significant difference (P<0.05).Conclusion The expression of the serum SPAG9 in patients with cervical cancer increased significantly,and with the increase of clinical stage,low differentiation degree and lymph node metastases and showed a trend of increase significantly.The expression of the serum SPAG9 significantly reduced after treatment of cervical cancer patients,SPAG9 can be used as the markers of the occurrence,development,metastasis and prognosis of cervical cancer.%目的：检测子宫颈癌患者血清精子相关抗原9（SPAG9）的表达水平，并分析其在宫颈癌发生发展中的作用及临床意义。方法宫颈癌患者96例为观察组，临床分期：I~Ⅱ期45例、Ⅲ~Ⅳ期51例。病理分级：中高分化40例，低分化56例。鳞癌、腺癌分别44例和52例。无淋巴结转移患者54例，淋巴结转移42例。选取正常宫颈妇女84例为对照组，主要观察各组对象血清SPAG9水平，并检测不同临床分期、分化程度、肿瘤类型、淋巴结转移及治疗前后SPAG9水平。结果观察组患者血清SPAG9 OD值（193.80±13.61），高于对照组（65.73±11.85），差异有统计学意义（P<0.05）。观察组治疗后SPAG9 OD值（117.69±12.30），低于治疗前，差异有统计学意义（P<0.05）。宫颈癌患者Ⅲ~Ⅳ期、低分化、淋巴结转移患者血清SPAG9 OD值分别为（227.61±13.21）、（213.19±12.86）和（219.85±12.93），均高于Ⅰ~Ⅱ期、中高分化及淋巴结未转移患者，差异均有统计学意义（P<0.05）。结论宫颈癌患者血清SPAG9的表达显著升高，并随着临床分期的增加、分化程度的降低及淋巴结转移而呈现增高趋势，宫颈癌患者治疗后SPAG9显著降低，SPAG9有可能作为宫颈癌的发生、发展、转移及预后的标记物。